Higher vitamin B12 level at Parkinson's disease diagnosis is associated with lower risk of future dementia

With your risk of getting Parkinsons as a result of your stroke, JUST MAYBE YOU WANT YOUR DOCTOR TO BE COMPETENT ENOUGH TO GIVE YOU THE CORRECT PROTOCOL ON B12. UP TO YOU HOW YOU WANT TO HANDLE THIS, LET IT SLIDE OR CONTACT THE BOARD OF DIRECTORS AND HAVE EVERYONE FIRED. 

My Dad had Parkinson's with dementia, I am not going down that route. 

Look at the dosing info here from WebMD. But remember you can do nothing without your doctor's prescription.

VITAMIN B12

 

Parkinson’s Disease May Have Link to Stroke March 2017

 

Higher vitamin B12 level at Parkinson's disease diagnosis is associated with lower risk of future dementia

• Stuart J. McCarter
• Cole Stang
• Pierpaolo Turcano
• 
  
• Farwa Ali
• James H. Bower
• Rodolfo Savica
• Show all authors

Published:March 17, 2020DOI:https://doi.org/10.1016/j.parkreldis.2020.03.009

Highlights

• •
  Treatment for non-motor features of Parkinson's disease are limited.
• •
  Higher risk of future dementia in patients with lower vitamin B12 levels at Parkinson's disease diagnosis.
• •
  Duration of Parkinson's disease symptoms and older age increase dementia risk.
• •
  Cognitively impaired Parkinson's disease patients tend to have lower B12 levels.
• •
  Vitamin B12 deserves further study for possible disease modifying effects in Parkinson's disease.

Abstract

Introduction

To determine whether vitamin B12 level at Parkinson's disease (PD) diagnosis predicts time to develop dementia.

Methods

We utilized a population-based cohort of Parkinsonism patients to examine the relationship between serum vitamin B12 at the time of PD diagnosis and dementia risk. Receiver operating curves were calculated for vitamin B12 cutoffs maximizing sensitivity and specificity for determining who developed dementia. Time from Parkinsonism diagnosis to dementia, death, or censoring was calculated utilizing Kaplan-Meier analysis and Cox-proportional hazard models.

Results

PD patients who did not develop dementia had higher baseline levels of vitamin B12 at PD diagnosis (648.5 ng/L vs 452 ng/L, p < 0.05) than those who developed dementia. Dementia risk was significantly lower in the 3rd tertile compared with 2nd tertile and trended towards significance compared to the 1st tertile. Each 100 unit increase in vitamin B12 level had a hazard ratio of 0.31 (95% CI 0.44–0.95) for future dementia (p < 0.05). Vitamin B12 cutoff of <587 ng/L was 87% sensitive and 70% specific (AUC 0.79, 95% CI 0.60–0.98) distinguishing patients with dementia. PD patients with vitamin B12 levels <587 ng/L were 5.4 times more likely to develop dementia, with 50% having dementia within 5 years of PD diagnosis compared with 11% in those with a vitamin B12 level of ≥587 ng/L (p < 0.05).  Now we just need to know EXACTLY the daily dose needed per bodyweight. 

Conclusion

Higher levels of serum vitamin B12 at PD diagnosis correlate with lower risk of future dementia. The role of vitamin B12 in the development of dementia among PD patients deserves further evaluation.

Highlights • Treatment for non-motor features of Parkinson's disease are limited. • Higher risk of future dementia in patients with lower vitamin B12 levels at Parkinson's disease diagnosis. • Duration of Parkinson's disease symptoms and older age increase dementia risk. • Cognitively impaired Parkinson's disease patients tend to have lower B12 levels. • Vitamin B12 deserves further study for possible disease modifying effects in Parkinson's disease. Abstract Introduction To determine whether vitamin B12 level at Parkinson's disease (PD) diagnosis predicts time to develop dementia. Methods We utilized a population-based cohort of Parkinsonism patients to examine the relationship between serum vitamin B12 at the time of PD diagnosis and dementia risk. Receiver operating curves were calculated for vitamin B12 cutoffs maximizing sensitivity and specificity for determining who developed dementia. Time from Parkinsonism diagnosis to dementia, death, or censoring was calculated utilizing Kaplan-Meier analysis and Cox-proportional hazard models. Results PD patients who did not develop dementia had higher baseline levels of vitamin B12 at PD diagnosis (648.5 ng/L vs 452 ng/L, p < 0.05) than those who developed dementia. Dementia risk was significantly lower in the 3rd tertile compared with 2nd tertile and trended towards significance compared to the 1st tertile. Each 100 unit increase in vitamin B12 level had a hazard ratio of 0.31 (95% CI 0.44–0.95) for future dementia (p < 0.05). Vitamin B12 cutoff of